SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that they will be hosting a booth at the 63rd Annual 2018 Caribbean Public Health Agency (CARPHA) Health Research Conference in St. Kitts & Nevis on June 14-16.
Co-Diagnostics, Inc. CEO Dwight Egan remarked, “We are excited to be attending this important event following the recent advancement in our CoPrimers™ platform technology in multiplex tests for SNP detection and the announcement of our CoPrimer technology being used in a research project conducted by the Wang Group at Stanford University. This event is an excellent opportunity to network with researchers and health professionals that attend from across the Caribbean Region, Latin America, North America and Europe.”
The Company has several key laboratory placements in the region and views this conference as a powerful forum for Co-Diagnostics to communicate the benefits of the Company’s infectious disease molecular tests, and the heightened specificity of the Company’s CoPrimer platform which enables robust multiplexing within a single reaction. Co-Diagnostics’ proprietary platform also has broad applications for agriculture and liquid biopsy for early cancer detection.
Mr. Egan continued, “We believe our marketing efforts in the Caribbean and Central American regions are making significant inroads and setting the stage for substantive, material revenue as the Company’s products are released as fully approved diagnostics. We anticipate being able to release news on those fronts in the very near future, and that our prospects will look even brighter as we continue to build on our current momentum.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with a proprietary diagnostic testing technology and development platform that intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and license the use of its platform to other non-competing developers.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “feel,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.